Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. ACP-101 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 3.2 across the same-window beat baseline.
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. ACP-101 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 3.2 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.7. Daybue appears in 1 tracked Healthcare story from February 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Daybue. Shared-story counts are live from our verified record — not editorial picks.
Fiscal Milestone
ACADIA reports record quarterly revenue and achieves annual GAAP profitability.
Trial Setback
Phase 3 ADVANCE-2 trial for pimavanserin in schizophrenia fails to meet primary endpoint.
Commercial Launch
Daybue officially enters the U.S. market with strong initial uptake.
FDA Approval
Daybue (trofinetide) approved as the first treatment for Rett syndrome.
ACADIA Pharmaceuticals reported a transformative fourth quarter, highlighted by the rapid commercial expansion of Daybue for Rett syndrome and the steady performance of Nuplazid. The company has successfully achieved GAAP profitability, signaling a robust shift toward a diversified rare disease and neurology portfolio.
Source: finance.yahoo.com · finance.yahoo.com
Daybue is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
